Heart rhythm showdown: ablation vs. electric shock for AF
NCT ID NCT06096246
First seen Jun 26, 2026 ยท Last updated Jun 26, 2026
Summary
This study compares two procedures for treating persistent atrial fibrillation (AF): catheter ablation (which scars tiny areas in the heart to block faulty signals) and DC cardioversion (an electric shock to restore normal rhythm). Researchers want to see which one better prevents AF from coming back. About 208 adults with persistent AF lasting less than 2 years will be randomly assigned to one of the two procedures and monitored with an implanted loop recorder.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Catheter ablation (pulmonary vein isolation) and DC cardioversion
- What this could lead to
- If ablation proves superior, it could become the preferred first-line procedure for persistent atrial fibrillation, reducing recurrence and the need for repeat procedures.
- What could go wrong
- This is a relatively small (208 participants) randomized trial. Ablation is an invasive procedure with risks like bleeding, infection, or heart damage, and results may not apply to all AF patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC ARRHYTHMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barts Heart Centre
RECRUITINGLondon, EC1A 7BE, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a chest scan shortcut dangerous heart rhythm surgery?
- Can a cholesterol drug keep atrial fibrillation at bay after ablation?
- Which ablation method best tames persistent AF? a Head-to-Head trial aims to find out
- Weight-Loss drug tirzepatide may help keep heart rhythm steady after ablation
- Wearable heart monitor works during scans, study finds
- Extra ablation target may cut AF recurrence in persistent cases